- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About AEROVATE THERAPEUTICS INC
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The Company's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The Company has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. It anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.
Stock Analysis
